TY - JOUR
T1 - De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation
T2 - Report of a case
AU - takeishi, kazuki
AU - Shirabe, Ken
AU - Toshima, Takeo
AU - Ikegami, Toru
AU - Morita, Kazutoyo
AU - Fukuhara, Takasuke
AU - Motomura, Takashi
AU - Mano, Yohei
AU - Uchiyama, Hideaki
AU - Soejima, Yuji
AU - Taketomi, Akinobu
AU - Maehara, Yoshihiko
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2011/7
Y1 - 2011/7
N2 - Interferon (IFN), which is the only possible agent for recurrent hepatitis C after liver transplantation, may cause serious immune-related disorders. We report a case of de novo autoimmune hepatitis (AIH), which developed subsequent to switching from 2b pegylated interferon-α (peg-IFN) to 2a peg-IFN after living donor liver transplantation (LDLT). A 51-year-old man with hepatitis C-associated liver cirrhosis underwent LDLT. About 13 months after the initiation of antiviral therapy, in the form of type 2b peg-IFN with ribavirin, a negative serum hepatitis C virus (HCV)-RNA titer was confirmed. Thereafter, the 2b peg-IFN was switched to 2a peg-IFN, 3 months after which severe liver dysfunction developed, despite a constantly negative HCV-RNA. Liver biopsy showed portal and periportal inflammatory infiltrates including numerous plasma cells, indicating AIH. He was treated with steroid pulse treatment, followed by high-level immunosuppression maintenance, but eventually died of Pneumocystis pneumonitis 4 months after the diagnosis of de novo AIH.
AB - Interferon (IFN), which is the only possible agent for recurrent hepatitis C after liver transplantation, may cause serious immune-related disorders. We report a case of de novo autoimmune hepatitis (AIH), which developed subsequent to switching from 2b pegylated interferon-α (peg-IFN) to 2a peg-IFN after living donor liver transplantation (LDLT). A 51-year-old man with hepatitis C-associated liver cirrhosis underwent LDLT. About 13 months after the initiation of antiviral therapy, in the form of type 2b peg-IFN with ribavirin, a negative serum hepatitis C virus (HCV)-RNA titer was confirmed. Thereafter, the 2b peg-IFN was switched to 2a peg-IFN, 3 months after which severe liver dysfunction developed, despite a constantly negative HCV-RNA. Liver biopsy showed portal and periportal inflammatory infiltrates including numerous plasma cells, indicating AIH. He was treated with steroid pulse treatment, followed by high-level immunosuppression maintenance, but eventually died of Pneumocystis pneumonitis 4 months after the diagnosis of de novo AIH.
UR - http://www.scopus.com/inward/record.url?scp=79960334474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960334474&partnerID=8YFLogxK
U2 - 10.1007/s00595-010-4392-z
DO - 10.1007/s00595-010-4392-z
M3 - Article
C2 - 21748625
AN - SCOPUS:79960334474
SN - 0941-1291
VL - 41
SP - 1016
EP - 1019
JO - Surgery Today
JF - Surgery Today
IS - 7
ER -
